Latest Hotspot

EC Grants Marketing Approval for EirGenix's Biosimilar for Breast Cancer

1 December 2023
3 min read

EirGenix Inc. has delivered news regarding the receipt of a marketing endorsement from the European Commission for their trastuzumab biosimilar medication (EG12014). This product is prepped for commercialization by their business collaborator, Sandoz.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The EU's marketing authorization will be applicable to the management of human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metastatic stomach cancers. This is the same as the approved indications by the EC for the reference biologic, Herceptin®.

Sandoz AG and EirGenix entered into a licensing contract in April 2019. As per this contract, EirGenix Inc. will continue to shoulder the development and production of trastuzumab, while Sandoz will acquire the rights to market the medicine globally upon approval. Breast and stomach cancers rank among the most frequently reported in Europe, and in combination, they contribute to nearly 200,000 deaths every year. Biosimilars have a huge potential to boost cancer care by significantly enhancing access to crucial medicaments.

Every year, more than 355,000 women are diagnosed with breast cancer, and with 92,000 annual fatalities, it is the leading cause of cancer mortality among females. Stomach cancer ranks sixth in prevalence among all cancer types, and with 107,000 deaths every year, it is the fourth leading cause of cancer-related deaths in Europe. In about 20% of breast cancer and 30% of stomach cancer cases identified, an overexpression of HER2 protein is noticed which leads to uncontrolled cell growth and division.

HER2 cancers are extremely aggressive forms of cancer that react positively to targeted therapy. The overall European authorization of EG12014 enlarges the access to a vital, high-quality cure for breast and stomach cancers, thus reducing the disease burden on patients and producing meaningful savings for healthcare systems for longer-term sustainability.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, Word

描述已自动生成

According to the data provided by the Synapse Database, As of November 30, 2023, there are 527 investigational drugs for the HER2 target, including 175 indications, 554 R&D institutions involved, with related clinical trials reaching 3389, and as many as 53151 patents.

EirGenix's trastuzumab biosimilar drug (EG12014) also received market approval by TFDA in June. The application of the health insurance pricing was approved by the National Health Insurance Administration under the Ministry of Health and Welfare in mid-September, paving the way for the formal launch of the product in Taiwan. 

A screenshot of a cell phone

Description automatically generated

Screening Sequences In Bulk? FTO Clearance Is Just A Few Clicks Away
Bio Sequence
2 min read
Screening Sequences In Bulk? FTO Clearance Is Just A Few Clicks Away
1 December 2023
Batch sequence searches are even quicker with new batch search reports and ability to save all patent results to your workspace in one click. Learn how Bio lets you search hundreds of sequences for FTO clearance in a matter of minutes!
Read →
EU Commission Greenlights KAFTRIO® Paired with Ivacaftor to treat Cystic Fibrosis in Kids Aged 2-5
Latest Hotspot
3 min read
EU Commission Greenlights KAFTRIO® Paired with Ivacaftor to treat Cystic Fibrosis in Kids Aged 2-5
1 December 2023
Vertex Pharmaceuticals has announced that the European Commission has approved an expanded label for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat cystic fibrosis in children aged 2 to 5 with at least one F508del mutation in the CFTR gene.
Read →
Unveiling the Secrets of IL-17A Inhibitors: Stay Updated with the Latest Advances
Unveiling the Secrets of IL-17A Inhibitors: Stay Updated with the Latest Advances
29 November 2023
IL-17A inhibitors are a class of drugs that target the cytokine IL-17A, playing a crucial role in treating inflammation and autoimmune diseases.
Read →
Initial Participant Registered for the Phase 1 Investigation of MRX-5
Latest Hotspot
3 min read
Initial Participant Registered for the Phase 1 Investigation of MRX-5
29 November 2023
Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. revealed that the first volunteer has been enlisted for the initial Phase I clinical examination of its innovative antibiotic MRX-5 in Australia.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.